공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

세계의 코로나바이러스 관련 제휴(2014-2021년)

Global Coronavirus Partnering 2014-2021

리서치사 Current Partnering, a division of Wildwood Ventures Limited
발행일 2021년 10월 상품 코드 997391
페이지 정보 영문 650+ Pages
가격
US $ 3,495 ₩ 4,185,000 PDF (Single User License)
US $ 5,245 ₩ 6,280,000 PDF (Multi User License - 2 to 5 Users)
US $ 10,495 ₩ 12,567,000 PDF (Single Site License - 6+ Users)
US $ 17,495 ₩ 20,950,000 PDF (Global License)


세계의 코로나바이러스 관련 제휴(2014-2021년) Global Coronavirus Partnering 2014-2021
발행일 : 2021년 10월 페이지 정보 : 영문 650+ Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

코로나바이러스에 관한 최근(2014-2021년간) 제휴 거래 동향에 대해 분석했으며, 전체적인 거래 성립 건수 추, 재무 측면(지불 조건)의 경향, 주요 기업의 거래 성립 동향, 계약 조건 경향, 기술별/치료 표적별 경향, 최근의 주요 제휴 거래 상세 정보를 정리하여 전해드립니다.

개요

제1장 서론

제2장 코로나바이러스 관련 계약 동향

  • 서론
  • 오랜 세월에 걸치는 코로나바이러스 관련 제휴
  • 거래 유형별 코로나바이러스 관련 제휴
  • 산업 부문별 코로나바이러스 관련 제휴
  • 개발 단계별 코로나바이러스 관련 제휴
  • 기술 유형별 코로나바이러스 관련 제휴
  • 치료 적응증별 코로나바이러스 관련 제휴

제3장 코로나바이러스 관련의 제휴 금전적 거래 조건

  • 서론
  • 코로나바이러스 관련 제휴의 금전적 조건 공개
  • 코로나바이러스 관련 제휴의 거래 총액
  • 코로나바이러스 계약의 선불금
  • 코로나바이러스 계약의 마일스톤 지불
  • 코로나바이러스의 로열티율

제4장 주요 코로나바이러스 계약과 계약 업체

  • 서론
  • 코로나바이러스 관련 제휴에서 가장 활발
  • 코로나바이러스로 가장 활발한 계약 업체 리스트
  • 주요 코로나바이러스 계약 : 금액 기준

제5장 코로나바이러스 계약 문서 디렉토리

  • 서론
  • 코로나바이러스 계약 문서를 열람 가능한 경우

제6장 치료 표적별 코로나바이러스 계약

  • 서론
  • 코로나바이러스 치료 표적별 계약

부록

  • 부록1 - 기업 A-Z별, 2014-2021년간 코로나바이러스 거래 디렉토리
  • 부록2 - 거래 유형별, 2014-2021년간 코로나바이러스 거래 디렉토리
  • 부록3 - 개발 단계별, 2014-2021년간 코로나바이러스 거래 디렉토리
  • 부록4 - 기술 유형별, 2014-2021년간 코로나바이러스 거래 디렉토리
  • 계약에 관한 기타 자료
  • 계약 유형의 정의
  • Wildwood Ventures에 대해
  • 현재의 제휴
  • 현재의 계약
  • Current Partnering에서의 최근 보고서 타이틀
LSH 21.04.15

The Global Coronavirus Partnering 2014-2021 report provides comprehensive understanding and unprecedented access to the coronavirus partnering agreements entered into by the worlds leading healthcare companies.

Global Coronavirus Partnering 2014 to 2021 provides the full collection of Coronavirus disease deals signed between the world's pharmaceutical and biotechnology companies since 2014.

Trends in Coronavirus partnering deals

Financial deal terms for headline, upfront and royalty by stage of development

Coronavirus partnering agreement structure

Coronavirus partnering contract documents

Top Coronavirus deals by value

Most active Coronavirus dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Coronavirus disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Coronavirus deals.

The report presents financial deal terms values for Coronavirus deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Coronavirus dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Coronavirus dealmaking since 2014 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Coronavirus deals since 2014. Deals are listed by headline value. The chapter includes the top 25 most active Coronavirus dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Coronavirus deals since 2014 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Coronavirus partnering deals by specific Coronavirus target announced since 2014. The chapter is organized by specific Coronavirus therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Coronavirus partnering deals signed and announced since 2014. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Coronavirus partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Coronavirus technologies and products.

Report scope

Global Coronavirus Partnering 2014 to 2021 is intended to provide the reader with an in-depth understanding and access to Coronavirus trends and structure of deals entered into by leading companies worldwide.

Global Coronavirus Partnering 2014 to 2021 includes:

  • Trends in Coronavirus dealmaking in the biopharma industry since 2014
  • Access to headline, upfront, milestone and royalty data
  • Access to numerous Coronavirus deal contract documents
  • Comprehensive access to over 1000 Coronavirus deal records
  • The leading Coronavirus deals by value since 2014
  • Most active Coronavirus dealmakers since 2014

In Global Coronavirus Partnering 2014 to 2021, available deals and contracts are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication
  • Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Coronavirus Partnering 2014-2021 report provides comprehensive access to available deals and contract documents for over 1000 Coronavirus deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are the sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

Global Coronavirus Partnering 2014 to 2021 provides the reader with the following key benefits:

  • In-depth understanding of Coronavirus deal trends since 2014
  • Access Coronavirus deal headline, upfront, milestone and royalty data
  • Research hundreds of actual contracts between Coronavirus partner companies
  • Comprehensive access to over 1000 links to actual Coronavirus deals entered into by the world's biopharma companies
  • Indepth review of Coronavirus deals entered into by the top 25 most active dealmakers
  • Benchmark the key deal terms companies have agreed in previous deals
  • Identify key terms under which companies partner Coronavirus opportunities
  • Uncover companies actively partnering Coronavirus opportunities

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Coronavirus dealmaking

  • 2.1. Introduction
  • 2.2. Coronavirus partnering over the years
  • 2.3. Coronavirus partnering by deal type
  • 2.4. Coronavirus partnering by industry sector
  • 2.5. Coronavirus partnering by stage of development
  • 2.6. Coronavirus partnering by technology type
  • 2.7. Coronavirus partnering by therapeutic indication

Chapter 3 -Financial deal terms for Coronavirus partnering

  • 3.1. Introduction
  • 3.2. Disclosed financials terms for Coronavirus partnering
  • 3.3. Coronavirus partnering headline values
  • 3.4. Coronavirus deal upfront payments
  • 3.5. Coronavirus deal milestone payments
  • 3.6. Coronavirus royalty rates

Chapter 4 - Leading Coronavirus deals and dealmakers

  • 4.1. Introduction
  • 4.2. Most active in Coronavirus partnering
  • 4.3. List of most active dealmakers in Coronavirus
  • 4.4. Top Coronavirus deals by value

Chapter 5 - Coronavirus contract document directory

  • 5.1. Introduction
  • 5.2. Coronavirus partnering deals where contract document available

Chapter 6 - Coronavirus dealmaking by therapeutic target

  • 6.1. Introduction
  • 6.2. Deals by Coronavirus therapeutic target

Appendices

  • Appendix 1 - Directory of Coronavirus deals by company A-Z 2014 to 2021
  • Appendix 2 - Directory of Coronavirus deals by deal type 2014 to 2021
  • Appendix 3 - Directory of Coronavirus deals by stage of development 2014 to 2021
  • Appendix 4 - Directory of Coronavirus deals by technology type 2014 to 2021
  • Further reading on dealmaking
  • Deal type definitions

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from CurrentPartnering

Table of figures

  • Figure 1: Coronavirus partnering since 2014
  • Figure 2: Coronavirus partnering by deal type since 2014
  • Figure 3: Coronavirus partnering by industry sector since 2014
  • Figure 4: Coronavirus partnering by stage of development since 2014
  • Figure 5: Coronavirus partnering by technology type since 2014
  • Figure 6: Coronavirus partnering by indication since 2014
  • Figure 7: Coronavirus deals with a headline value
  • Figure 8: Coronavirus deals with upfront payment values
  • Figure 9: Coronavirus deals with milestone payment
  • Figure 10: Coronavirus deals with royalty rates
  • Figure 11: Active Coronavirus dealmaking activity- 2014 to 2021
  • Figure 12: Top Coronavirus deals by value since 2014
Back to Top
전화 문의
F A Q